Volatile anesthetics and AKI: Risks, mechanisms, and a potential therapeutic window

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 884-892

  Fukazawa, Kyota ^a   Lee, H Thomas ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; INHALATION ANESTHETIC AGENT; INTERLEUKIN 11; LYSOPHOSPHOLIPID RECEPTOR; LYSOPHOSPHOLIPID S1P; SK 1 ENZYME; SPHINGOMYELIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CAVEOLA; CELL GROWTH; CELL SURVIVAL; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE CELL; LIPID SOLUBILITY; LYMPHOCYTE MIGRATION; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; RENAL PROTECTION; REVIEW; SECOND MESSENGER; ANIMAL; DRUG EFFECT; ISCHEMIA-REPERFUSION; ISCHEMIC RENAL FAILURE; KIDNEY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; REPERFUSION INJURY; RISK FACTOR;

ACUTE RENAL FAILURE; ISCHEMIA-REPERFUSION; ISCHEMIC RENAL FAILURE;

ACUTE KIDNEY INJURY; ANESTHETICS, INHALATION; ANIMALS; HUMANS; INTRAOPERATIVE COMPLICATIONS; KIDNEY; POSTOPERATIVE COMPLICATIONS; REPERFUSION INJURY; RISK FACTORS;

EID: 84906541074     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013111215     Document Type: Review

References (89)

1. Chertow GM, Burdick E, Honour M, Bonventre JV, BatesDW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J AmSoc Nephrol 16: 3365-3370, 2005
2. Jones DR, Lee HT: Perioperative renal protection. Best Pract Res Clin Anaesthesiol 22: 193-208, 2008
3. Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS: Community-based incidence of acute renal failure. Kidney Int 72: 208-212, 2007
4. Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committee: Early acute kidney injury and sepsis: A multicentre evaluation. Crit Care 12: R47, 2008
5. Thakar CV, Christianson A, Freyberg R, Almenoff P, Render ML: Incidence and outcomes of acute kidney injury in intensive care units: A Veterans Administration study. Crit Care Med 37: 2552-2558, 2009
6. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 294: 813-818, 2005
7. Liaño F, Junco E, Pascual J, Madero R, Verde E; The Madrid Acute Renal Failure Study Group: The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int Suppl 66: S16-S24, 1998
8. Lafrance JP, Miller DR: Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol 21: 345-352, 2010
9. Abelha FJ, Botelho M, Fernandes V, Barros H: Determinants of postoperative acute kidney injury. Crit Care 13: R79, 2009
10. Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, Parikh CR; TRIBE-AKI Consortium: Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 23: 905-914, 2012
11. Ratliff BB, Rabadi MM, Vasko R, Yasuda K, Goligorsky MS: Messengers without borders: Mediators of systemic inflammatory response in AKI. J Am Soc Nephrol 24: 529-536, 2013
12. Bellomo R, Kellum JA, Ronco C: Defining and classifying acute renal failure: Fromadvocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 33: 409-413, 2007
13. Faubel S: Pulmonary complications after acute kidney injury. Adv Chronic Kidney Dis 15: 284-296, 2008
14. Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, Crow M, Ross CA, Mattson MP, Rabb H: Acute kidney injury leads to inflammation and functional changes in the brain. J AmSoc Nephrol 19: 1360-1370, 2008
15. Desborough JP: The stress response to trauma and surgery. Br J Anaesth 85: 109-117, 2000
16. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW: Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology 101: 1313-1324, 2004
17. Pagel PS, Kampine JP, Schmeling WT, Warltier DC: Comparison of the systemic and coronary hemodynamic actions of desflurane, isoflurane, halothane, and enflurane in the chronically instrumented dog. Anesthesiology 74: 539-551, 1991
18. Miller RD: Miller's Anesthesia, Philadelphia, Elsevier, 2005
19. Smith I, NathansonM,White PF: Sevoflurane-a long-awaited volatile anaesthetic. Br J Anaesth 76: 435-445, 1996
20. Crandell WB, Pappas SG, Macdonald A: Nephrotoxicity associated with methoxyflurane anesthesia. Anesthesiology 27: 591-607, 1966
21. Kharasch ED: Adverse drug reactions with halogenated anesthetics. Clin Pharmacol Ther 84: 158-162, 2008
22. Mazze RI: Fluorinated anaesthetic nephrotoxicity: An update. Can Anaesth Soc J 31: S16-S22, 1984
23. Spencer EM, Willatts SM, Prys-Roberts C: Plasma inorganic fluoride concentrations during and after prolonged (greater than 24 h) isoflurane sedation: Effect on renal function. Anesth Analg 73: 731-737, 1991
24. Cousins MJ, Mazze RI: Methoxyflurane nephrotoxicity. A study of dose response in man. JAMA 225: 1611-1616, 1973
25. Anders MW: Formation and toxicity of anesthetic degradation products. Annu Rev Pharmacol Toxicol 45: 147-176, 2005
26. Bito H, Ikeuchi Y, Ikeda K: Effects of low-flow sevoflurane anesthesia on renal function: Comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Anesthesiology 86: 1231-1237, 1997
27. Yang H, Liang G, Hawkins BJ, Madesh M, Pierwola A, Wei H: Inhalational anesthetics induce cell damage by disruption of intracellular calcium homeostasis with different potencies. Anesthesiology 109: 243-250, 2008
28. Warltier DC, al-Wathiqui MH, Kampine JP, Schmeling WT: Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology 69: 552-565, 1988
29. Xiong L, Zheng Y, Wu M, Hou L, Zhu Z, Zhang X, Lu Z: Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg 96: 233-237, table of contents, 2003
30. Lv X, Yang L, Tao K, Liu Y, Yang T, ChenG, Yu W, Lv H, Wu F: Isoflurane preconditioning at clinically relevant doses induce protective effects of heme oxygenase-1 on hepatic ischemia reperfusion in rats. BMC Gastroenterol 11: 31, 2011
31. Pagel PS: Postconditioning by volatile anesthetics: Salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth 22: 753-765, 2008
32. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, Himmelfarb J, Zager RA: MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 22: 165-175, 2011
33. Heinzelmann M, Mercer-Jones MA, Passmore JC: Neutrophils and renal failure. Am J Kidney Dis 34: 384-399, 1999
34. Devarajan P: Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17: 1503-1520, 2006
35. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, Ju ST, Okusa MD: Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol 20: 1744-1753, 2009
36. Kinsey GR, Sharma R, Okusa MD: Regulatory T cells in AKI. J Am Soc Nephrol 24: 1720-1726, 2013
37. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, Lobo PI, Okusa MD: Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 23: 1528-1537, 2012
38. Obal D, Rascher K, Favoccia C, Dettwiler S, Schlack W: Post-conditioning by a short administration of desflurane reduced renal reperfusion injury after differing of ischaemia times in rats. Br J Anaesth 97: 783-791, 2006
39. Hashiguchi H, Morooka H, Miyoshi H, MatsumotoM, Koji T, Sumikawa K: Isoflurane protects renal function against ischemia and reperfusion through inhibition of protein kinases, JNK and ERK. Anesth Analg 101: 1584-1589, 2005
40. Kim M, Ham A, Kim JY, Brown KM, D'Agati VD, Lee HT: The volatile anesthetic isoflurane induces ecto-59-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury. Kidney Int 84: 90-103, 2013
41. Song JH, Kim M, Park SW, Chen SW, Pitson SM, Lee HT: Isoflurane via TGF-beta1 release increases caveolae formation and organizes sphingosine kinase signaling in renal proximal tubules. Am J Physiol Renal Physiol 298: F1041-F1050, 2010
42. Meyer H: Zur Theorie der Alkoholnarkose. Arch Exp Pathol Pharmacol 42: 109-118, 1899
43. Overton C: Studien über die Narkose zugleich ein Beitrag zur allgemeinen Pharmakologie. Trans Faraday Soc 33: 1062-1068, 1901
44. Franks NP: General anaesthesia: From molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 9: 370-386, 2008
45. Hoetzel A, Geiger S, Loop T, Welle A, Schmidt R, Humar M, Pahl HL, Geiger KK, Pannen BH: Differential effects of volatile anesthetics on hepatic heme oxygenase-1 expression in the rat. Anesthesiology 97: 1318-1321, 2002
46. Urner M, Limbach LK, Herrmann IK, Müller-Edenborn B, Roth-Z'Graggen B, Schlicker A, Reyes L, Booy C, Hasler M, Stark WJ, Beck- Schimmer B: Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol 45: 617-624, 2011
47. O'Rourke B: Myocardial K(ATP) channels in preconditioning. Circ Res 87: 845-855, 2000
48. Kersten JR, Gross GJ, Pagel PS, Warltier DC: Activation of adenosine triphosphateregulated potassium channels: Mediation of cellular and organ protection. Anesthesiology 88: 495-513, 1998
49. Cope DK, Impastato WK, Cohen MV, Downey JM: Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology 86: 699-709, 1997
50. Lee HT, Kim M, Kim J, Kim N, Emala CW: TGF-beta1 release by volatile anesthetics mediates protection against renal proximal tubule cell necrosis. Am J Nephrol 27: 416-424, 2007
51. Huynh ML, Fadok VA, Henson PM: Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41-50, 2002
52. Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL, Henson PM: Cross-talk between ERK and p38MAPKmediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem277: 14884-14893, 2002
53. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890-898, 1998
54. Lee HT, Chen SW, Doetschman TC, Deng C, D'Agati VD, Kim M: Sevoflurane protects against renal ischemia and reperfusion injury in mice via the transforming growth factorbeta1 pathway. Am J Physiol Renal Physiol 295: F128-F136, 2008
55. Zhou Y, Lekic T, Fathali N, Ostrowski RP, Martin RD, Tang J, Zhang JH: Isoflurane posttreatment reduces neonatal hypoxic-ischemic brain injury in rats by the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway. Stroke 41: 1521-1527, 2010
56. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, Spiegel S: Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147: 545-558, 1999
57. Spiegel S, Milstien S: Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407, 2003
58. Davaille J, Li L, Mallat A, Lotersztajn S: Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem 277: 37323-37330, 2002
59. Monick MM, Mallampalli RK, Bradford M, McCoy D, Gross TJ, Flaherty DM, Powers LS, Cameron K, Kelly S, Merrill AH Jr, Hunninghake GW: Cooperative prosurvival activity by ERK and Akt in human alveolar macrophages is dependent on high levels of acid ceramidase activity. J Immunol 173: 123-135, 2004
60. Kim DS, Hwang ES, Lee JE, Kim SY, Park KC: Sphingosine-1-phosphate promotes mouse melanocyte survival via ERK and Akt activation. Cell Signal 15: 919-926, 2003
61. Kim M, Kim M, Park SW, Pitson SM, Lee HT: Isoflurane protects human kidney proximal tubule cells against necrosis via sphingosine kinase and sphingosine-1-phosphate generation. Am J Nephrol 31: 353-362, 2010
62. Bakar AM, Park SW, Kim M, Lee HT: Isoflurane protects against human endothelial cell apoptosis by inducing sphingosine kinase-1 via ERK MAPK. Int J Mol Sci 13: 977-993, 2012
63. Kim M, Park SW, Kim M, D'Agati VD, Lee HT: Isoflurane activates intestinal sphingosine kinase to protect against bilateral nephrectomyinduced liver and intestine dysfunction. Am J Physiol Renal Physiol 300: F167-F176, 2011
64. Colgan SP, Eltzschig HK, Eckle T, Thompson LF: Physiological roles for ecto-59-nucleotidase (CD73). Purinergic Signal 2: 351-360, 2006
65. Kim J, KimM, Song JH, Lee HT: Endogenous A1 adenosine receptors protect against hepatic ischemia reperfusion injury in mice. Liver Transpl 14: 845-854, 2008
66. Csóka B, Németh ZH, Rosenberger P, Eltzschig HK, Spolarics Z, Pacher P, Selmeczy Z, Koscsó B, Himer L, Vizi ES, Blackburn MR, Deitch EA, Haskó G: A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 185: 542-550, 2010
67. Park SW, Chen SW, Kim M, Brown KM, D'Agati VD, Lee HT: Protection against acute kidney injury via A(1) adenosine receptormediated Akt activation reduces liver injury after liver ischemia and reperfusion in mice. J Pharmacol Exp Ther 333: 736-747, 2010
68. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J: Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 203: 2639-2648, 2006
69. Hart ML, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK: Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182: 3965-3968, 2009
70. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Köhle C, Kloor D, Thompson LF, Osswald H, Eltzschig HK: Protective role of ecto-59-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 18: 833-845, 2007
71. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK: Cardioprotection by ecto-59-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115: 1581-1590, 2007
72. Lee HT, Gallos G, Nasr SH, Emala CW: A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 15: 102-111, 2004
73. LeeHT, EmalaCW: Protective effects of renal ischemic preconditioning and adenosine pretreatment: Role of A(1) and A(3) receptors. Am J Physiol Renal Physiol 278: F380-F387, 2000
74. Park SW, Kim M, Kim JY, Brown KM, Haase VH, D'Agati VD, Lee HT: Proximal tubule sphingosine kinase-1 has a critical role in A1 adenosine receptor-mediated renal protection from ischemia. Kidney Int 82: 878-891, 2012
75. Ham A, Kim M, Kim JY, Brown KM, Yeh J, D'Agati VD, Lee HT: Critical role of interleukin-11 in isoflurane-mediated protection against ischemic acute kidney injury in mice. Anesthesiology 119: 1389-1401, 2013
76. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K: Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 153: 305-312, 1992
77. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA: Randomized placebocontrolled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15: 3368-3377, 1997
78. Du X, Williams DA: Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89: 3897-3908, 1997
79. Kim JY, Kim M, Ham A, Brown KM, Greene RW, D'Agati VD, Lee HT: IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI. J Am Soc Nephrol 24: 1558-1570, 2013
80. Eltzschig HK, Carmeliet P: Hypoxia and inflammation. NEnglJMed364: 656-665, 2011
81. Eltzschig HK, Sitkovsky MV, Robson SC: Purinergic signaling during inflammation. N Engl J Med 367: 2322-2333, 2012
82. Lee HT, Park SW, Kim M, Ham A, Anderson LJ, Brown KM, D'Agati VD, Cox GN: Interleukin-11 protects against renal ischemia and reperfusion injury. Am J Physiol Renal Physiol 303: F1216-F1224, 2012
83. Benzonana LL, Perry NJ, Watts HR, Yang B, Perry IA, Coombes C, Takata M, Ma D: Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology 119: 593-605, 2013
84. Raphael J, Zuo Z, Abedat S, Beeri R, Gozal Y: Isoflurane preconditioning decreases myocardial infarction in rabbits via up-regulation of hypoxia inducible factor 1 that ismediated by mammalian target of rapamycin. Anesthesiology 108: 415-425, 2008
85. Zhang L, Huang H, Cheng J, Liu J, Zhao H, Vizcaychipi MP, Ma D: Pre-treatment with isoflurane ameliorates renal ischemic-reperfusion injury in mice. Life Sci 88: 1102-1107, 2011
86. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; ACC/AHA Task Force Members: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in collaboration with the American SocietyofEchocardiography,American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 116: 1971-1996, 2007
87. Beck-Schimmer B, Breitenstein S, Bonvini JM, Lesurtel M, Ganter M, Weber A, Puhan MA, Clavien PA: Protection of pharmacological postconditioning in liver surgery: Results of a prospective randomized controlled trial. Ann Surg 256: 837-844; discussion 844-835, 2012
88. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, TurinaMI, von Segesser LK, Pasch T, Spahn DR, Zaugg M: Preconditioning by sevoflurane decreases biochemical markers for myocardial andrenal dysfunction in coronary arterybypass graft surgery: A double-blinded, placebocontrolled, multicenter study. Anesthesiology 98: 1315-1327, 2003
89. Lee JH, Joo DJ, Kim JM, Park JH, Kim YS, Koo BN: Preconditioning effects of the anesthetic administered to the donor on grafted kidney function in living donor kidney transplantation recipients. Minerva Anestesiol 79: 504-514, 2013